Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in South Korea / NCT06479421
Recruiting Observational

A Clinical Study for Developing Artificial Intelligence(AI)-Based Clustering Model for Personalized Medicine in Acute Respiratory Failure

NCT06479421 · tracked via the Priya Life Science South Korea tracker
Sponsor
Samsung Medical Center
Phase
Observational
Started
2023-08-14
Last updated
2026-04-28

Condition(s) studied

Acute Respiratory Failure

Study summary

The investigators will prospectively collect clinical information to develop a clustering analysis model and confirm phenotype for patients with acute respiratory failure who admit to the intensive care unit and require oxygen supply beyond a high flow nasal cannula, and a control group without acute respiratory failure. and clinical characteristics and prognosis will be compared.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
\# Inclusion Criteria: \- Acute Respiratory Failure group Among patients admitted to the internal medicine intensive care unit at Samsung Seoul Hospital, if all of the following conditions are met: 1\) Age 18 or older 2) Patients who require treatment with high flow nasal cannula (HFNC), non-invasive ventilation (NIV (BIPAP or CPAP)), or mechanical ventilation (MV) due to acute respiratory failure. \- control group For comparative analysis, among patients admitted to the internal medicine intensive care unit at Samsung Seoul Hospital who meet all of the following conditions, they are registered as a control group with the consent of the subjects and undergo the same research procedure. 1. Age 18 or older 2. Patients who do not require high flow nasal cannula (HFNC), non-invasive ventilation (NIV (BIPAP or CPAP)), or mechanical ventilation (MV) treatment * Exclusion Criteria: If any of the following criteria applies, participants will not be permitted to participate in this clinical trial. 1. Patients 48 hours after oxygen treatment (HFNC, NIV (BIPAP or CPAP), MV) 2. Patients transferred from another hospital 3. Patients with limitations in treatment

Primary outcome measure(s)

  • Hospital Mortality — From date of admission until the date of hospital discharge or date of death from any cause, whichever came first, assessed up to 1 year
    clinical outcomes - Hospital Mortality

Trial sites (1)

FacilityCityRegionStatus
Samsung Medical Center Seoul Gangnam Recruiting

More Samsung Medical Center trials in South Korea

IVUS Versus FFR for Non-infarct Related Artery Lesions in Patients With Multivessel Disease and Acute MI Recruiting
Genomic Profiling of Pancreatic Cystic Tumors Starting soon
Head and Neck Cancer Omics/Integrated Precision Medicine (HOPE) Recruiting
Korean Stroke Cohort for Functioning and Rehabilitation-II Active, not recruiting
Prospective Cohort for Tumor Bed Boost Radiotherapy in HER2 Positive Breast Cancer Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06479421 on ClinicalTrials.gov ↗ ← All trials in South Korea